TP53 mutation with STK11/EGFR WT identified a tumor-immune profile by enriched expression of PD-L1 and CD8+ T cells in the TME, by the upregulation of chemokines CXCL9, 10, 11, and a stronger expression of genes involved in antigen processing and MHC-1 presentation, indicating a higher immunogenicity. This evidence concerns the gene STK11 and neoplasm.